Osterweis Capital Management Inc. Acquires Shares of 167,095 PROCEPT BioRobotics Corporation $PRCT

Osterweis Capital Management Inc. bought a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the second quarter, Holdings Channel.com reports. The firm bought 167,095 shares of the company’s stock, valued at approximately $3,773,000.

Several other institutional investors have also recently made changes to their positions in PRCT. Versant Capital Management Inc lifted its stake in shares of PROCEPT BioRobotics by 994.5% in the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after purchasing an additional 1,084 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in PROCEPT BioRobotics by 436.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after purchasing an additional 746 shares during the period. Center for Financial Planning Inc. purchased a new stake in PROCEPT BioRobotics in the fourth quarter worth $40,000. Cache Advisors LLC bought a new position in PROCEPT BioRobotics in the first quarter worth $42,000. Finally, Essential Partners LLC lifted its position in PROCEPT BioRobotics by 7,071.4% during the first quarter. Essential Partners LLC now owns 2,008 shares of the company’s stock valued at $50,000 after buying an additional 1,980 shares during the period. Institutional investors own 89.46% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Larry L. Wood bought 23,900 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $20.85 per share, with a total value of $498,315.00. Following the completion of the acquisition, the chief executive officer owned 23,900 shares of the company’s stock, valued at approximately $498,315. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have sold 1,000 shares of company stock worth $28,480. 4.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PRCT shares. Citigroup cut shares of PROCEPT BioRobotics to a “hold” rating in a report on Thursday, July 2nd. Evercore set a $23.00 price target on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Wells Fargo & Company lowered shares of PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective on the stock. in a research note on Wednesday, August 5th. Jefferies Financial Group restated a “hold” rating and issued a $20.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Finally, UBS Group lowered shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 target price for the company. in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $28.00.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Several law firms, including Hagens Berman, Rosen, Kaplan Fox, Pomerantz, and others, are soliciting investors who purchased PRCT securities between February 28, 2024, and February 25, 2026. Investors have until September 22, 2026, to seek appointment as lead plaintiff. Hagens Berman class-action announcement
• Negative Sentiment: The underlying lawsuit alleges that PROCEPT misled investors about demand and recurring sales trends by using repeated late-quarter bulk discounts to encourage handpiece purchases, potentially inflating reported revenue signals. The complaint also points to weaker-than-expected unit handpiece sales and excess inventory held by customers. These are allegations, and the company’s liability has not been established. Kahn Swick & Foti securities-fraud announcement
• Negative Sentiment: The legal action creates potential costs, management distraction, and continued uncertainty around PROCEPT’s sales practices, inventory levels, and the sustainability of its growth. The concentration of similar investor-alert releases may keep attention on the lawsuit even though the announcements do not represent new operating results or a new company disclosure. Glancy Prongay Wolke securities-fraud deadline alert

PROCEPT BioRobotics Trading Up 1.6%

NASDAQ PRCT opened at $21.60 on Wednesday. PROCEPT BioRobotics Corporation has a 12 month low of $16.67 and a 12 month high of $42.43. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. The stock’s fifty day moving average price is $20.36 and its 200-day moving average price is $24.06. The stock has a market cap of $1.24 billion, a P/E ratio of -11.13 and a beta of 0.89.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The company had revenue of $94.50 million during the quarter, compared to analysts’ expectations of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.PROCEPT BioRobotics’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.35) EPS. As a group, equities analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.